A SINGLE-ARM MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Trial Profile

A SINGLE-ARM MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Ofatumumab (Primary) ; Pentostatin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms PCO
  • Most Recent Events

    • 11 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
    • 02 Mar 2016 According to European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
    • 23 Dec 2015 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top